Skip to main content

Jim Shamp

Director of Public Relations
Phone number: 
919-549-8889
E-mail: 
jim_shamp@ncbiotech.org

Jim Shamp writes and edits news and other Web copy, brochures and other internal and external Biotechnology Center materials, and supports the Corporate Communications unit’s marketing and media relations activities.

Background

Shamp joined the Biotechnology Center in 2005, after more than eight years as science and health reporter for the Durham Herald-Sun. He brought to NCBiotech nearly four decades of professional experience in writing, editing, marketing and advertising. This includes some 18 years of newspaper, broadcast, wire service and Web journalism in Illinois, Indiana, Michigan and North Carolina as well as a decade of public-relations activity at major global pharmaceutical companies' headquarters in Michigan and North Carolina. He has also started or been involved in establishing several entrepreneurial ventures.

He participates in a variety of professional, community-service and educational boards and committees, including the National Association of Science Writers.

Shamp holds a B.S. degree in communications from Manchester (Ind.) College (now Manchester University).

Blogs

A sow and a soybean walk into a lab.

It might be the start of a good joke. I don’t know. But Tim Xtreme Lee has done the due diligence to extract the funny from the corn.  

The North Carolina Biotechnology Center has been expanding its support for marine biotechnology during the past decade, and it’s proving to be a great investment for the state.

 

-- Shutterstock image

Cempra is a Chapel Hill company that’s developing antibiotics to treat scary bacterial infections.

Besides the four active Nobel Laureates conducting research at Duke and UNC, here are 13 others with N.C. connections who have also won the major global recognition.

When a chorus of cheers accompanies announcements like the $1.85 billion Novo Nordisk expansion in Clayton, the echo is a reminder: it's a team effort.

Two key state funding programs are proving to be a great match to get new North Carolina life science companies off the ground.

Life science entrepreneurs routinely turn to the loan options available from the North Carolina Biotechnology Center after tapping friends, family and credit cards. But many of those same NCBiotech portfolio companies also get much-needed early survival lifelines in the form of grants from the One North Carolina Small Business Fund, managed by the state Department of Commerce’s N.C. Office of Science, Technology and Innovation.

As we weigh the GSK layoff announcement, let’s be glad for what we have and celebrate what’s to come. Sure, things will never be the same. But the fact is, they never were anyway.

Certified Financial Planner Lisa Gabriel provided useful financial tips for people facing job loss during the September 29 Jobs Network gathering at NCBiotech.

The National Institute of Allergy and Infectious Diseases just added $4.1 million to a $22 million, five-year grant made a year ago, to help BioCryst develop an anti-viral drug that could prevent a terrible Ebola outbreak -- next time one happens.

Bob Ingram is one of those rare people who can spin a roomful of people in circles with words. He did it again this week as he accepted a Lifetime Achievement Award from the Triangle Business Journal. And appropriately enough, the room he was spinning was the classy ballroom at the Umstead Hotel in Cary.

Articles

First Flight Venture Center has set a date of September 13, 2017 to roll back the doors of Hangar6, calling it “an advanced rapid prototyping facility.”

The billion-dollar cell culture Seqirus vaccine factory in Holly Springs has hit yet another milestone. The highly skilled workers at the sprawling factory southeast of Raleigh successfully produced the world’s first cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather than in eggs.

CiVentiChem has received its first U.S. Food and Drug Administration approval for a generic commercial active pharmaceutical ingredient (API) manufactured at its Cary headquarters.

G1 Therapeutics, a clinical-stage oncology company based in Research Triangle Park, became a publicly traded entity today with a $105 million initial public offering of seven million shares of stock priced at $15 a share.

A California surgeon has performed the first U.S. bone graft using a pliable foam produced by Research Triangle Park–based medical biomaterials company CURASAN Inc.

Ticket sales close Wednesday, May 10, for a May 17 event featuring a talk by the immediate past U.S. FDA commissioner, Robert Califf, M.D., MACC.

Glenmark Pharmaceuticals, an India-based global pharmaceutical company, is hiring at its pharmaceutical manufacturing facility in the Union County community of Monroe, outside Charlotte.

WUNC, the University of North Carolina Public Radio station, devoted a 12-minute segment of the weekday show “The State of Things” to the state’s life science sector today.

RTP's AgTech Accelerator has made a $5 million investment to establish a new animal health company, Skyline Vet Pharma, to in-license and develop drug delivery technologies aimed at improving veterinary treatment of companion animals – primarily dogs and cats.

Triangle attorney and business leader Ravila Gupta will become president and CEO of the Council for Entrepreneurial Development (CED), effective April 17.